A detailed history of Barclays PLC transactions in Moderna, Inc. stock. As of the latest transaction made, Barclays PLC holds 1,192,897 shares of MRNA stock, worth $170 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,192,897
Previous 158,700 651.67%
Holding current value
$170 Million
Previous $15.8 Million 705.45%
% of portfolio
0.04%
Previous 0.01%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$85.37 - $115.44 $7.23 Million - $9.78 Million
84,733 Added 7.65%
1,192,897 $127 Million
Q4 2023

Feb 15, 2024

BUY
$69.51 - $104.43 $11.3 Million - $17 Million
163,264 Added 17.28%
1,108,164 $110 Million
Q3 2023

Nov 07, 2023

BUY
$96.41 - $126.61 $3.28 Million - $4.31 Million
34,008 Added 3.73%
944,900 $97.6 Million
Q2 2023

Aug 03, 2023

BUY
$118.5 - $160.53 $30.4 Million - $41.1 Million
256,295 Added 39.15%
910,892 $111 Million
Q1 2023

May 04, 2023

SELL
$135.66 - $197.02 $110 Million - $160 Million
-813,653 Reduced 55.42%
654,597 $101 Million
Q4 2022

Feb 13, 2023

SELL
$118.38 - $210.04 $14.3 Million - $25.3 Million
-120,454 Reduced 7.58%
1,468,250 $264 Million
Q3 2022

Nov 03, 2022

BUY
$118.07 - $194.18 $47.2 Million - $77.6 Million
399,454 Added 33.59%
1,588,704 $188 Million
Q2 2022

Aug 12, 2022

SELL
$117.13 - $176.59 $14.6 Million - $22.1 Million
-124,917 Reduced 9.51%
1,189,250 $170 Million
Q1 2022

May 16, 2022

SELL
$126.46 - $235.05 $251 Million - $467 Million
-1,987,952 Reduced 60.2%
1,314,167 $226 Million
Q4 2021

Feb 14, 2022

BUY
$225.82 - $368.51 $462 Million - $754 Million
2,047,118 Added 163.12%
3,302,119 $839 Million
Q3 2021

Nov 09, 2021

BUY
$221.9 - $484.47 $146 Million - $318 Million
657,299 Added 109.97%
1,255,001 $483 Million
Q2 2021

Aug 13, 2021

BUY
$129.91 - $234.98 $24 Million - $43.5 Million
185,034 Added 44.84%
597,702 $140 Million
Q1 2021

May 13, 2021

SELL
$109.18 - $185.98 $20.8 Million - $35.5 Million
-190,618 Reduced 31.6%
412,668 $54 Million
Q4 2020

Feb 11, 2021

SELL
$65.74 - $169.86 $12.4 Million - $32.2 Million
-189,310 Reduced 23.88%
603,286 $63 Million
Q3 2020

Nov 12, 2020

BUY
$54.34 - $94.85 $19.4 Million - $33.8 Million
356,811 Added 81.88%
792,596 $56.1 Million
Q2 2020

Aug 12, 2020

BUY
$29.67 - $80.0 $9.57 Million - $25.8 Million
322,685 Added 285.31%
435,785 $28 Million
Q1 2020

May 13, 2020

BUY
$17.78 - $31.58 $1.68 Million - $2.98 Million
94,258 Added 500.25%
113,100 $3.39 Million
Q4 2019

Feb 10, 2020

SELL
$13.93 - $21.28 $127,640 - $194,988
-9,163 Reduced 32.72%
18,842 $369,000
Q3 2019

Nov 14, 2019

SELL
$12.26 - $18.07 $173,172 - $255,238
-14,125 Reduced 33.53%
28,005 $446,000
Q2 2019

Aug 14, 2019

SELL
$13.7 - $28.34 $420,603 - $870,066
-30,701 Reduced 42.15%
42,130 $617,000
Q1 2019

May 15, 2019

BUY
$14.45 - $23.7 $1.05 Million - $1.73 Million
72,831 New
72,831 $1.48 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $55.8B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.